Tip60 promotes prostate cancer cell proliferation by translocation of androgen receptor into the nucleus

Prostate

Volumn 70, Issue 5, 2010, Pages 540-554

  Shiota, Masaki ^a   Yokomizo, Akira ^a   Masubuchi, Daisuke ^a   Tada, Yasuhiro ^a   Inokuchi, Junichi ^a   Eto, Masatoshi ^b   Uchiumi, Takeshi ^a   Fujimoto, Naohiro ^c   Naito, Seiji ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

^c UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

Acetylation; Androgen deprivation therapy; Castration resistant prostate cancer; Nuclear localization signal; Prostate specific antigen

Indexed keywords

ANDROGEN RECEPTOR; LUCIFERASE; PROTEIN; PROTEIN TIP60; UNCLASSIFIED DRUG; AR PROTEIN, HUMAN; HISTONE ACETYLTRANSFERASE; HTATIP PROTEIN, HUMAN;

ACETYLATION; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BIOASSAY; CANCER CELL; CASTRATION; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL GROWTH; CELL NUCLEUS; CELL PROLIFERATION; CONTROLLED STUDY; CYTOPLASM; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GENE DELETION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HORMONAL REGULATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN TRANSPORT; QUANTITATIVE ASSAY; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; WESTERN BLOTTING; ACTIVE TRANSPORT; CHEMISTRY; MALE; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROSTATE TUMOR; TUMOR CELL LINE;

ACTIVE TRANSPORT, CELL NUCLEUS; CELL LINE, TUMOR; CELL NUCLEUS; CELL PROLIFERATION; HISTONE ACETYLTRANSFERASES; HUMANS; MALE; PROSTATIC NEOPLASMS; PROTEIN TRANSPORT; RECEPTORS, ANDROGEN; TRANSCRIPTION, GENETIC;

EID: 77949893772     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21088     Document Type: Article

References (42)

1. Debes JD, Tindall DJ. The role of androgens and the androgen receptor in prostate cancer. Cancer Lett 2002;187:1-7. (Pubitemid 35279326)
2. Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: Directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 2005;23:8253-8261.
3. Gregory CW, Hamil KG, Kim D, Hall SH, Pretlow TG, Mohler JL, French FS. Androgen receptor expression in androgen-independent prostate cancer is associated with increased expression of androgen-regulated genes. Cancer Res 1998;58:5718-5724. (Pubitemid 29006412)
4. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG, Sawyers CL. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004;10:33-39. (Pubitemid 38524696)
5. Zegarra-Moro OL, Schmidt LJ, Huang H, Tindall DJ. Disruption of androgen function inhibits proliferation of androgen-refractory prostate cancer cells. Cancer Res 2002;62:1008-1013. (Pubitemid 34160279)
6. Linja MJ, Savinainen KJ, Saramäki OR, Tammela TL, Vessella RL, Visakorpi T. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res 2001;61:3550-3555. (Pubitemid 32694958)
7. Taplin ME, Rajeshkumar B, Halabi S, Werner CP, Woda BA, Picus J, Stadler W, Hayes DF, Kantoff PW, Vogelzang NJ, Small EJ. Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. J Clin Oncol 2003;21:2673-2678. (Pubitemid 46606310)
8. Zoubeidi A, Zardan A, Beraldi E, Fazli L, Sowery R, Rennie P, Nelson C, Gleave M. Cooperative interaction between androgen receptor (AR) and heat-shock protein 27 facilitate AR transcriptional activity. Cancer Res 2007;67:10455-10465. (Pubitemid 350070821)
9. Park SY, Yu X, Ip C, Mohler JL, Bogner PN, Park YM. Peroxiredoxin 1 interacts with androgen receptor and enhances its transactivation. Cancer Res 2007;67:9294-9303. (Pubitemid 47535918)
10. Miyamoto H, Rahman M, Takatera H, Kang HY, Yeh S, Chang HC, Nishimura K, Fujimoto N, Chang C. A dominant-negative mutant of androgen receptor coregulator ARA54 inhibits androgen receptor-mediated prostate cancer growth. J Biol Chem 2002;277:4609-4617.
11. Fujimoto N, Yeh S, Kang HY, Inui S, Chang HC, Mizokami A, Chang C. Cloning and characterization of androgen receptor coactivator, ARA55, in human prostate. J Biol Chem 1999;274:8316-8321. (Pubitemid 129518232)
12. Bevan CL, Hoare S, Claessens F, Heery DM, Parker MG. The AF1 and AF2 domains of the androgen receptor interact with distinct regions of SRC1. Mol Cell Biol 1999;19:8383-8392. (Pubitemid 30414032)
13. Kamine J, Elangovan B, Subramanian T, Coleman D, Chinnadurai G. Identification of a cellular protein that specifically interacts with the essential cysteine region of the HIV-1 Tat transactivator. Virology 1996;216:357-366. (Pubitemid 26083380)
14. Yamamoto T, Horikoshi M. Novel substrate specificity of the histone acetyltransferase activity of HIV-1-Tat interactive protein Tip60. J Biol Chem 1997;272:30595-30598. (Pubitemid 27527486)
15. Ikura T, Ogryzko VV, Grigoriev M, Groisman R, Wang J, Horikoshi M, Scully R, Qin J, Nakatani Y. Involvement of the TIP60 histone acetylase complex in DNA repair and apoptosis. Cell 2000;102:463-473.
16. Brady ME, Ozanne DM, Gaughan L, Waite I, Cook S, Neal DE, Robson CN. Tip60 is a nuclear hormone receptor coactivator. J Biol Chem 1999;274:17599-17604. (Pubitemid 129519110)
17. Gaughan L, Logan IR, Cook S, Neal DE, Robson CN. Tip60 and histone deacetylase 1 regulate androgen receptor activity through changes to the acetylation status of the receptor. J Biol Chem 2002;277:25904-25913.
18. Halkidou K, Gnanapragasam VJ, Mehta PB, Logan IR, Brady ME, Cook S, Leung HY, Neal DE, Robson CN. Expression of Tip60, an androgen receptor coactivator, and its role in prostate cancer development. Oncogene 2003;22:2466-2477. (Pubitemid 36560730)
19. Brinkmann AO, Faber PW, van Rooij HC, Kuiper GG, Ris C, Klaassen P, van der Korput JA, Voorhorst MM, van Laar JH, Mulder E, Trapman J. The human androgen receptor: Domain structure, genomic organization and regulation of expression. J Steroid Biochem 1989;34:307-310.
20. Tyagi RK, Lavrovsky Y, Ahn SC, Song CS, Chatterjee B, Roy AK. Dynamics of intracellular movement and nucleocytoplasmic recycling of the ligand-activated androgen receptor in living cells. Mol Endocrinol 2000;14:1162-1174. (Pubitemid 32260478)
21. Cutress ML, Whitaker HC, Mills IG, Stewart M, Neal DE. Structural basis for the nuclear import of the human androgen receptor. J Cell Sci 2008;121:957-968.
22. Marcelli M, Zoppi S, Grino PB, Griffin JE, Wilson JD, McPhaul MJ. A mutation in the DNA-binding domain of the androgen receptor gene causes complete testicular feminization in a patient with receptor-positive androgen resistance. J Clin Invest 1991;87:1123-1126.
23. Gottlieb B, Beitel LK, Lumbroso R, Pinsky L, Trifiro M. Update of the androgen receptor gene mutations database. Hum Mutat 1999;14:103-114. (Pubitemid 29372777)
24. Nazareth LV, Stenoien DL, Bingman WE III, James AJ, Wu C, Zhang Y, Edwards DP, Mancini M, Marcelli M, Lamb DJ, Weigel NL. A C619Y mutation in the human androgen receptor causes inactivation and mislocalization of the receptor with concomitant sequestration of SRC-1 (steroid receptor coactivator 1). Mol Endocrinol 1999;13:2065-2075. (Pubitemid 30637267)
25. Tilley WD, Buchanan G, Hickey TE, Bentel JM. Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. Clin Cancer Res 1996;2:277-285. (Pubitemid 26074615)
26. Zoppi S, Marcelli M, Deslypere JP, Griffin JE, Wilson JD, McPhaul MJ. Amino acid substitutions in the DNA-binding domain of the human androgen receptor are a frequent cause of receptor-binding positive androgen resistance. Mol Endocrinol 1992;6:409-415.
27. Fu M, Wang C, Reutens AT, Wang J, Angeletti RH, Siconolfi-Baez L, Ogryzko V, Avantaggiati ML, Pestell RG. p300 and p300/cAMP-response element-binding protein-associated factor acetylate the androgen receptor at sites governing hormone-dependent transactivation. J Biol Chem 2000;275:20853-20860. (Pubitemid 30457679)
28. Fu M, Wang C, Wang J, Zhang X, Sakamaki T, Yeung YG, Chang C, Hopp T, Fuqua SA, Jaffray E, Hay RT, Palvimo JJ, Jänne OA, Pestell RG. Androgen receptor acetylation governs transactivation and MEKK1-induced apoptosis without affecting in vitro sumoylation and trans-repression function. Mol Cell Biol 2002;22:3373-3388. (Pubitemid 34453978)
29. Fu M, Rao M, Wang C, Sakamaki T, Wang J, Di Vizio D, Zhang X, Albanese C, Balk S, Chang C, Fan S, Rosen E, Palvimo JJ, Jänne OA, Muratoglu S, Avantaggiati ML, Pestell RG. Acetylation of androgen receptor enhances coactivator binding and promotes prostate cancer cell growth. Mol Cell Biol 2003;23:8563-8575. (Pubitemid 37433362)
30. Tso CL, McBride WH, Sun J, Patel B, Tsui KH, Paik SH, Gitlitz B, Caliliw R, van Ophoven A, Wu L, deKernion J, Belldegrun A. Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells. Cancer J 2000;6:220-233.
31. Patel BJ, Pantuck AJ, Zisman A, Tsui KH, Paik SH, Caliliw R, Sheriff S, Wu L, deKernion JB, Tso CL, Belldegrun AS. CL1-GFP: An androgen independent metastatic tumor model for prostate cancer. J Urol 2000;164:1420-1425.
32. Tomura A, Goto K, Morinaga H, Nomura M, Okabe T, Yanase T, Takayanagi R, Nawata H. The subnuclear three-dimensional image analysis of androgen receptor fused to green fluorescence protein. J Biol Chem 2001;276:28395-28401. (Pubitemid 37391549)
33. Mizokami A, Gotoh A, Yamada H, Koller ET, Matsumoto T. Tumor necrosis factor-alpha represses androgen sensitivity in the LNCaP prostate cancer cell line. J Urol 2000;164:800-805. (Pubitemid 30637637)
34. Shiota M, Izumi H, Onitsuka T, Miyamoto N, Kashiwagi E, Kidani A, Yokomizo A, Naito S, Kohno K. Twist promotes tumor cell growth through YB-1 expression. Cancer Res 2008;68:98-105.
35. Shiota M, Izumi H, Onitsuka T, Miyamoto N, Kashiwagi E, Kidani A, Hirano G, Takahashi M, Naito S, Kohno K. Twist and p53 reciprocally regulate target genes via direct interaction. Oncogene 2008;27:5543-5553.
36. Shiota M, Izumi H, Miyamoto N, Onitsuka T, Kashiwagi E, Kidani A, Hirano G, Takahashi M, Ono M, Kuwano M, Naito S, Sasaguri Y, Kohno K. Ets regulates peroxiredoxin1 and 5 expressions through their interaction with the high mobility group protein B1. Cancer Sci 2008;99:1950-1959.
37. Shiota M, Izumi H, Tanimoto A, Takahashi M, Miyamoto N, Kashiwagi E, Kidani A, Hirano G, Masubuchi D, Fukunaka Y, Yasuniwa Y, Naito S, Nishizawa S, Sasaguri Y, Kohno K. Programmed cell death protein 4 down-regulates Y-box binding protein-1 expression via a direct interaction with Twist1 to suppress cancer cell growth. Cancer Res 2009;69:3148-3156.
38. Georget V, Térouanne B, Lumbroso S, Nicolas JC, Sultan C. Trafficking of androgen receptor mutants fused to green fluorescent protein: A new investigation of partial androgen insensitivity syndrome. J Clin Endocrinol Metab 1998;83:3597-3603. (Pubitemid 28500896)
39. Sykes SM, Mellert HS, Holbert MA, Li K, Marmorstein R, Lane WS, McMahon SB. Acetylation of the p53 DNA-binding domain regulates apoptosis induction. Mol Cell 2006;24:841-851.
40. Sun Y, Jiang X, Chen S, Fernandes N, Price BD. A role for the Tip60 histone acetyltransferase in the acetylation and activation of ATM. Proc Natl Acad Sci USA 2005;102:13182-13187. (Pubitemid 41324998)
41. Tang Y, Luo J, Zhang W, Gu W. Tip60-dependent acetylation of p53 modulates the decision between cell-cycle arrest and apoptosis. Mol Cell 2006;24:827-839.
42. Miyamoto N, Izumi H, Noguchi T, Nakajima Y, Ohmiya Y, Shiota M, Kidani A, Tawara A, Kohno K. Tip60 is regulated by circadian transcription factor clock and is involved in cisplatin resistance. J Biol Chem 2008;283:18218-18226.